归真堂药业 specializes in the production and sale of traditional Chinese medicinal products, specifically targeting the use of bear bile and other herbal remedies as self-described.

归真堂药业

CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It also develops DTcP vaccine for infants and DTcP Booster vaccine, which are in Phase I clinical trial for addressing the weaker protection preventing pertussis after primary vaccination. Further, the company develops Tdcp Adolescent and Adult vaccine for treating pertussis; PBPV, a serotype-independent protein-based pneumococcal vaccine that is in Phase I clinical trial; PCV13i, a pneumococcal conjugate vaccine, which is in Phase I clinical trial; and TB Booster for the BCG-vaccinated population which is in Phase I clinical trial. In addition, it is developing various preclinical stage products, including DTcP-Hib Combo vaccine; CSB012 to treat adenovirus; CSB013 for ZIKA virus; CSB015 to treat meningitis; CSB016 for treating shingles; and CSB107 for polio. CanSino Biologics Inc. was incorporated in 2009 and is headquartered in Tianjin, the People's Republic of China.

Metric
Company Name	归真堂药业	CanSino Biologics Inc.
Symbol		6.18K
MSH ID	COM:GZTXD	COM:CANSINOTECH
Market	PRIVATE	STOCKS
Sector	Healthcare & Health Services	Healthcare
Industry	Pharmaceuticals	Drug Manufacturers - Specialty & Generic
Country	CN	CN
Stage
Employee Count		1.49K
Website	gztxd.com	cansinotech.com
LinkedIn
Founders

Metric
Market Cap		833.48M
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue		49.33M
Revenue (LTM)
Revenue (NTM)
Gross Profit		-61.30M
EBITDA		-204.75M
Operating Income		-237.96M
Net Income		-204.84M
EPS		-0.83
Diluted EPS		-0.83
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.14
Operating Profit Margin		-0.86
EBITDA Margin		-4.15
Net Profit Margin		-1.42
Return on Equity		-0.16
Return on Assets		-0.11
Return on Capital Employed		-0.08

GZTX

COM:GZTXD

归真堂药业

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		20.35
EV Multiple		-3.00

Metric
Days Sales Outstanding		485.87
Days Payables Outstanding		170.20
Days Inventory Outstanding		251.49
Operating Cycle		815.83
Cash Conversion Cycle		770.86
Asset Turnover		0.07

Metric
Operating Cash Flow		-125.47M
Free Cash Flow		-209.81M
Cash Flow to Debt		-0.12
Operating Cash Flow/Sales		-0.43
Free Cash Flow Yield		-0.25

Metric
Cash & Equivalents		389.80M
Accounts Receivable		36.74M
Inventory		48.75M
Goodwill
Debt to Capitalization		0.34
Debt to Assets		0.21
Current Ratio		2.24
Quick Ratio		2.22

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue		1.04
SG&A to Revenue		0.34